Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-designed mRNA 2.0 therapeutics for in vivo CAR-T cancer and autoimmune therapy; $35.8M raised with Amgen Ventures backing advancing KR-335 toward IND filing.
Kernal Biologics is a clinical-stage biotech developing AI-designed mRNA therapeutics for cancer and autoimmune diseases — using machine learning to engineer cell-type-specific mRNA sequences that direct therapeutic payloads (including CAR-T gene programs) to the right cells in vivo, enabling off-the-shelf CAR-T cancer therapy without the individualized cell extraction and ex vivo manufacturing process that makes current CAR-T treatments cost $400,000+ and require weeks of production time. The Y Combinator-backed company has raised $35.8 million including a $25 million Series A led by Hummingbird Ventures with participation from Amgen Ventures.
AI chemical reaction optimization with 95% accuracy for drug discovery synthesis parameters; $4.5M from Khosla Ventures and YC competing to automate pharmaceutical process chemistry development.
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists with AI systems that determine optimal reaction parameters (temperature, solvent, catalyst, concentration) for new chemical synthesis routes, achieving 95% accuracy in suggesting effective conditions for small-scale trials. Founded in 2023 and backed by Khosla Ventures, 468 Capital, 500 Global, and Y Combinator with $4.5 million raised including a $4 million seed round in April 2024, Yoneda Labs brings mathematical category theory foundations (the name references Yoneda's lemma in category theory) to chemistry AI.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.